Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study by Hwang, Thomas J. et al.
Delays in completion and results
reporting of clinical trials under
the Paediatric Regulation in the
European Union: A cohort study
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Hwang, Thomas J., Paolo A. Tomasi, and Florence T. Bourgeois.
2018. “Delays in completion and results reporting of clinical
trials under the Paediatric Regulation in the European
Union: A cohort study.” PLoS Medicine 15 (3): e1002520.
doi:10.1371/journal.pmed.1002520. http://dx.doi.org/10.1371/
journal.pmed.1002520.
Published Version doi:10.1371/journal.pmed.1002520
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981941
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE
Delays in completion and results reporting of
clinical trials under the Paediatric Regulation
in the European Union: A cohort study
Thomas J. Hwang1,2,3, Paolo A. Tomasi4, Florence T. Bourgeois1,2,5*
1 Computational Health Informatics Program, Boston Children’s Hospital, Boston, Massachusetts, United
States of America, 2 Center for Pediatric Therapeutics and Regulatory Science, Department of Medicine,
Boston Children’s Hospital, Boston, Massachusetts, United States of America, 3 Program on Regulation,
Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of
Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 4 European
Medicines Agency, London, United Kingdom, 5 Department of Pediatrics, Harvard Medical School, Boston,
Massachusetts, United States of America
* florence.bourgeois@childrens.harvard.edu
Abstract
Background
Few medicines have been approved for children, leading to rates of off-label prescribing
reported to be as high as 90%. In 2007, the European Union adopted the Paediatric Regula-
tion, which mandates that pharmaceutical companies conduct paediatric studies for all new
medicines, unless granted a waiver. We aimed to evaluate the availability of paediatric trial
results from studies required under the Paediatric Regulation for new medicines authorised
in the EU.
Methods and findings
The European Medicines Agency (EMA) public database of paediatric investigation plans
was searched for new medicines centrally authorised in the EU between 1 January 2010
and 31 December 2014 with at least 1 required paediatric study. For our study cohort of
paediatric clinical trials required for these medicines, we used internal EMA databases and
publicly available trial registries to determine changes to the planned completion date or
study design, rates of trial completion, time to trial completion, and results reporting (peer-
reviewed publication or posting on trial registry). Cox proportional hazards regression mod-
els were constructed to examine factors associated with study completion. A total of 326
paediatric clinical trials were required for 122 novel medicines authorised by the EMA
between 2010 and 2014. In all, 76% (247/326) of paediatric studies were not planned to be
completed until after the initial marketing authorisation. The planned completion dates for
50% (162/326) were further postponed by a median of 2.2 years. Overall, 38% (124/326) of
paediatric studies were completed as of 30 November 2017. The rate of trial completion for
paediatric studies planned to be completed after initial marketing authorisation was 23%
(56/247), versus 86% (68/79) for trials planned to be completed before authorisation (ad-
justed hazard ratio 0.11; 95% CI 0.06–0.19). Among completed studies, the results were
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reported in a public registry or in the peer-reviewed literature for 85% (105/124) at a median
of 1.1 years after study completion, and 60% (74/124) were published in a peer-reviewed
journal. Limitations of this study include the potential lack of generalisability to medicines not
authorised by the EMA and the possibility for more of these trials to be completed or pub-
lished in the future.
Conclusions
The completion of many paediatric studies required under the Paediatric Regulation has
been delayed. Paediatric studies planned to be completed after marketing authorisation
were associated with a lower likelihood of eventual completion, highlighting the need to
examine the implementation of current policies in ensuring timely availability of important
paediatric information.
Author summary
Why was this study done?
• Most new medicines are developed and tested in adults, and clinicians often need to
treat paediatric patients with products lacking paediatric safety, efficacy, or dosing
information.
• To increase the number of medicines that are appropriately studied in children, the
European Union adopted the Paediatric Regulation in 2007, requiring pharmaceutical
companies to study new medicines in children.
• Ten years since its implementation, there has been limited assessment of the availability
of paediatric trial information resulting from studies required under the regulation.
What did the researchers do and find?
• For all new medicines centrally authorised in the EU between 2010 and 2014, we identi-
fied those with paediatric trial requirements under the Paediatric Regulation. A total of
326 paediatric clinical trials were required for 122 medicines and comprised our study
cohort.
• After a median follow-up of roughly 7 years, 38% of paediatric trials had been com-
pleted, and 17% of medicines had all paediatric requirements fulfilled.
• Most paediatric studies (76%) were not planned to be completed until after marketing
authorisation. In addition, delays occurred due to changes in the planned completion
date, with 50% of studies extending the completion date at the request of pharmaceutical
companies.
• Overall, trials planned to be completed after marketing authorisation were associated
with an 89% lower likelihood of completion compared to trials with planned completion
before marketing authorisation.
Completion of clinical trials under the Paediatric Regulation in the European Union
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• The results for 85% of completed studies were published or publicly reported in a trial
registry, at a median of 1.1 years after the completion date.
What do these findings mean?
• Many paediatric studies required under the Paediatric Regulation have not been com-
pleted due to delays.
• Among paediatric trials that were completed, trial results were disseminated in a timely
fashion for a majority of the studies.
• Our findings highlight the need to examine the implementation of current policies—
including requirements around the timing of trial completion—to ensure timely avail-
ability of important paediatric information for new medicines.
Introduction
Historically, information on the safety, efficacy, and appropriate use of new medicines in chil-
dren has been lacking [1]. In one study, over 90% of surveyed paediatricians reported prescrib-
ing medicines off-label [2]. Over the years, this gap in available evidence has led to serious
unintended harms: for example, the off-label paediatric use of paroxetine was associated with
an increased risk of suicidal ideation and hostility, resulting in warnings by regulators that the
medicine should not be used in children and adolescents [3].
In 2007, the Paediatric Regulation made paediatric development of medicines mandatory
in the EU, establishing a system of obligations, rewards, and incentives to promote the study of
medicines in children and to improve the information available to clinicians on the use of
these products in paediatric populations [4,5]. The requirements were intended to address the
longstanding practice in which drugs were developed primarily for adults, and rarely evaluated
in children, but were necessarily subsequently used to treat paediatric patients. Under the Pae-
diatric Regulation, before applying for marketing authorisation, pharmaceutical companies
must agree with the European Medicines Agency (EMA) Paediatric Committee on a paediatric
investigation plan (PIP) aimed at generating the data necessary to authorise the medicine for
children. A PIP, which describes the studies to be carried out in children and the timing
planned for their completion, is required for all new medicines as well as new indications, new
routes of administration, and new pharmaceutical forms of existing authorised products,
unless a waiver is granted. A waiver may be granted, for example, because the condition does
not occur in children, because the product is unlikely to be effective or safe in children, or
because it would not provide a significant benefit compared to products already authorised.
The pharmaceutical company can receive a financial reward (a 6-month extension of patent
protection for the medicinal product) once it has completed all studies agreed on in the PIP
(see Box) [6]. The Paediatric Regulation further provides that the results of paediatric clinical
trials must be posted to the EU Clinical Trials Register within 6 months of completion [4].
The impact of the Paediatric Regulation on the timely completion of and dissemination of
results from paediatric trials is uncertain. In principle, the Paediatric Regulation calls for stud-
ies to be conducted before marketing authorisation applications are submitted (the Paediatric
Completion of clinical trials under the Paediatric Regulation in the European Union
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Regulation states ‘paediatric investigation plans should be submitted early during product
development, in time for studies to be conducted in the paediatric population, where appropri-
ate, before marketing authorisation applications are submitted’). However, several factors may
cause delays in study completion. For example, a pharmaceutical company can request to com-
plete a study after initial marketing authorisation, allowing the company to apply for market-
ing authorisation in other age groups (e.g., adults) before starting or completing paediatric
studies. The date of completion of these studies can be further postponed at the request of the
company via a modification of the PIP as agreed on with the EMA. In addition, the availability
of paediatric information may be delayed by varying rates of results reporting after trial com-
pletion [7] and completion of clinical trials in the post-authorisation period in general [8–13].
For example, one recent study found that 54% of US Food and Drug Administration (FDA)
postmarketing requirements and commitments had been completed after 5 to 6 years of fol-
low-up [9].
In this study, we examined the frequency and duration of delays and the completion of pae-
diatric clinical trials for new medicines centrally authorised in the EU after the entry into force
Box 1. Key provisions of the EU Paediatric Regulation
Entry into force (year): 2007
Paediatric development: Mandatory (unless waived)
Main reward: 6-month extension of the SPC (patent) for non-orphan products or
2-year extension of market exclusivity for orphan products
Types of products: New medicinal products; authorised products under patent/SPC if
applying for new indication, route, or form
Excluded products: Generic, hybrid, well-established use, traditional herbal, homeo-
pathic, and biosimilar products
Scope of paediatric development: Derived from adult indication, within same
condition
Timing of PIP or waiver submission: Early in drug development
Modification procedure: Sponsors may propose changes or request a waiver if key ele-
ments of an already agreed PIP are no longer workable or appropriate
Public access to PIP decisions: Yes
Require trial registration on public database: Yes
Timing of results submission and posting: Within 6 months of completion
Full or partial waivers in paediatric subgroups may be granted if the specific medicinal
product or a class of medicinal products is likely to be ineffective or unsafe in paediatric
patients, if the condition for which the medicine is intended occurs only in adults (or
only in some paediatric subsets), or if the medicine does not represent a significant ther-
apeutic benefit over existing treatments for paediatric patients.
EMA, European Medicines Agency; PIP, paediatric investigation plan; SPC, supplemen-
tary protection certificate.
Completion of clinical trials under the Paediatric Regulation in the European Union
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of the Paediatric Regulation. We evaluated the dissemination of the results of these trials
through reporting of key trial outcomes in public registries and peer-reviewed publications.
Methods
Study cohort
We used the EMA’s public registry of new marketing authorisations to identify all new medi-
cines centrally authorised in the EU between 1 January 2010 and 31 December 2014 (Fig 1)
[14]. The study time frame was chosen to allow at least 2 years of follow-up from the date of
marketing authorisation. We included all new medicinal products that were not previously
authorised in the EU, including chemical and biologic products and vaccines. Products that
were not subject to the obligations of the Paediatric Regulation (e.g., generic drugs; see Box)
were excluded from this analysis.
For each identified medicine, we searched the EMA’s public database of opinions and deci-
sions on PIPs to determine whether a PIP had been adopted (leading to publication of a PIP
opinion) or if a waiver of paediatric development requirements had been granted for the pro-
posed medical condition [15]. We validated this search with a review of the EMA European
public assessment reports, to arrive at a final list of new medicines authorised by the EMA dur-
ing our study period with paediatric study requirements (S1 Data). Our study cohort was
defined as paediatric clinical trials required for these medicines.
Fig 1. Study flowchart. Lowercase n’s refer to the number of medicines; uppercase N’s refer to the number of
associated paediatric trials identified from the published paediatric investigation plans (PIPs). Traditional herbal and
homeopathic products, those authorised under well-established use, and nationally authorised medicines were also
excluded.
https://doi.org/10.1371/journal.pmed.1002520.g001
Completion of clinical trials under the Paediatric Regulation in the European Union
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Data extraction
At the medicine level, we first extracted key information on each included medicine, including
date of initial marketing authorisation in the EU, indication, therapeutic area (WHO Anatom-
ical Therapeutic Chemical [ATC] code), and orphan status (a designation for medicines autho-
rised for rare diseases).
From the PIP opinion and, if applicable, any subsequent modifications, we then identified
all non-duplicate clinical trials included in the PIP and extracted information on the planned
start and end dates, size (number of enrolled participants), study population, and study type.
We categorised study type based on the primary study endpoints as (i) primarily efficacy stud-
ies, (ii) efficacy and safety studies, (iii) primarily safety studies, or (iv) pharmacokinetic/phar-
macodynamics (PK/PD) and dose-finding studies (hereafter ‘PK/PD studies’). We excluded
studies included in PIPs that did not plan to enrol any paediatric participants (e.g., adult PK/
PD or bioequivalence studies; N = 36) and trials whose completion dates predated the date
when the PIP opinion was published (N = 24). Data extraction was conducted by 2 investiga-
tors (TJH, FTB), with conflicts resolved by consensus.
For each paediatric study, we tracked changes in the study design and timeline. Once a PIP
is published, changes to paediatric studies can only be made through 1 or more procedures of
modification of the agreed PIP. These modification procedures can only be initiated at the
request of the sponsor. Using EMA’s internal database of paediatric applications, we identified
changes in the expected size of the trial, study endpoints, study populations, statistical meth-
ods, or treatment duration, and any other substantive changes to the trial. We also identified
changes in the planned completion date. The number and types of changes were extracted for
all modification procedures that had been completed and published by the EMA’s Paediatric
Committee through 31 January 2017.
To determine whether a study had been completed, we searched the EU Clinical Trials Reg-
ister (https://www.clinicaltrialsregister.eu) and the US National Institutes of Health’s Clinical-
Trials.gov registry (https://clinicaltrials.gov/), using the study name or a combination of the
medicine name, study population, study size, planned completion date, and study type. Both
the US and EU have requirements on trial registration and results posting that should techni-
cally cover all included paediatric trials. In the EU, since 2007, paediatric studies are required
to be registered in the EU Clinical Trials Register, and the results posted within 6 months of
study completion. In the US, applicable clinical trials initiated after 27 September 2007 are
required to be registered in ClinicalTrials.gov and to post results within 1 year after completion
of data collection for the primary outcome. We crosschecked the trial status reported on public
registries with compliance checks conducted by the EMA on PIP studies [16] and by searching
for other public and commercial mentions of the trial and its completion status.
Finally, we defined results reporting as a composite endpoint of (i) results posted on the EU
Clinical Trials Register or ClinicalTrials.gov and/or (ii) publication in a peer-reviewed journal.
As described above, we searched for paediatric trials on the EU Clinical Trials Register and
ClinicalTrials.gov and then identified whether and when results had been posted. We searched
Medline, Embase, and Web of Science for peer-reviewed publications of the paediatric trial,
and, for each publication, extracted the date of first publication online (if earlier than the publi-
cation date listed in the citation).
Statistical analyses
We assessed the time difference between the initially planned paediatric trial completion date
and the date of initial marketing authorisation granted by the European Commission (repre-
senting when the medicine is first available on the market) as well as the duration of granted
Completion of clinical trials under the Paediatric Regulation in the European Union
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extensions (i.e., delays) to the planned completion date. We calculated the unadjusted rate and
relative risk of study completion, the rate of completion of all clinical studies specified in a
given PIP, and the rate and median time to results reporting.
In adjusted analyses, we constructed multivariable logistic regression models to examine
factors associated with the likelihood of delays and Cox proportional hazards regression mod-
els to examine factors associated with study completion. Models included all variables of inter-
est regardless of statistical significance: therapeutic area (ATC code), study type, an indicator
variable for trials planned to be completed after (versus before) marketing authorisation, and a
time variable for the PIP opinion. In all models, robust standard errors were clustered by PIP.
All study analyses described above were conducted according to the project protocol agreed
upon prior to data collection, with a database lock in November 2017 (S1 Protocol). In a pre-
specified sensitivity analysis, we repeated our analysis of trial completion and results reporting
excluding PK/PD studies in order to address the possibility that PK/PD studies may be easier to
complete (and therefore more likely to be completed) than other studies. Since the conduct of
required paediatric studies may differ for medicines with versus without any initially intended
paediatric populations, we also performed a post hoc sensitivity analysis limiting our analysis to
the cohort of medicines authorised only in adults.
Statistical analyses were performed using Stata version 12 (StataCorp), and 2-tailed P
values< 0.05 were considered statistically significant.
Results
Of 246 new medicines (excluding generic and biosimilar products) that were authorised by the
EMA during our study period, 122 (50%) with PIPs were included (Fig 1); most of these medi-
cines were anti-infective (34, 28%), antineoplastic or immunomodulatory (23, 19%), or ali-
mentary or metabolic agents (17, 14%). These 122 medicines with PIPs were associated with
326 paediatric clinical trials, cumulatively planning to enrol 51,324 participants (Table 1; Fig
1). In all, 182 of 326 trials (56%) were primarily efficacy studies, 21 (6%) trials had both pri-
mary efficacy and safety endpoints, 70 (21%) trials had only safety primary endpoints, and 53
(16%) trials were PK/PD studies. The median duration of follow-up for all studies from the
date of PIP publication to 30 November 2017 was 7.6 years (IQR 6.5–8.4 years).
Delays and modifications of paediatric clinical trials
Most (247, 76%) paediatric studies were not planned to be completed until after the initial
marketing authorisation. Overall, the originally planned completion dates for 162 (50%) paedi-
atric studies (representing 78 [64%] of medicines) were extended through modification of the
PIP at the request of companies, resulting in a median delay of 2.2 years (IQR 1.1–3.8 years).
The majority (201, 62%) of paediatric studies had at least 1 modification (other than
changes to planned study completion date) after publication of the PIP, with a median of 2
modifications. Among these, 85 (26%) trials had changes to study population or inclusion/
exclusion criteria, 83 (25%) trials had changes to sample size, 73 (22%) had changes to statisti-
cal methods, and 69 (21%) had changes to study endpoints.
Most (60 of 83, 72%) modifications to sample size resulted in trials that were smaller than
originally planned. Among these trials with sample size modification, the median reduction in
trial size was 29% (IQR 20%–50%), corresponding to 4,032 total fewer participants and a
median reduction of 20 participants (IQR 10–77). The total number of modifications was sig-
nificantly associated with delays in both univariable (P = 0.001) and multivariable logistic
regression analyses (adjusted odds ratio 2.31; 95% CI 1.18–4.51; P = 0.02) (S1 Table).
Completion of clinical trials under the Paediatric Regulation in the European Union
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Completion of paediatric clinical trials
As of 30 November 2017, 124 of 326 (38%) paediatric clinical trials were completed, and all
clinical studies specified in the PIP were completed for 21 of 122 (17%) medicines. The rates of
trial completion 1, 2, and 5 years following PIP publication were 4%, 14%, and 34%, respec-
tively. The rates of completion were 51% for PK/PD studies, 32% for primarily efficacy studies,
38% for trials with both primary efficacy and safety endpoints, and 43% for primarily safety
studies (Table 2). There were no statistically significant differences in time to completion by
Table 1. Characteristics of paediatric trials (N = 326) for new medicines authorised by the EMA in 2010–2014.
Characteristic Number (%)
Therapeutic area
Alimentary and metabolism 44 (13.5%)
Blood 43 (13.2%)
Cardiovascular 14 (4.3%)
Genitourinary 9 (2.8%)
Anti-infective 75 (23.0%)
Antineoplastic and immunomodulatory 44 (13.5%)
Neurologic 53 (16.3%)
Respiratory 28 (8.6%)
Musculoskeletal and others 16 (4.9%)
PIP opinion year
2008 40 (12.3%)
2009 110 (33.7%)
2010 62 (19.0%)
2011 64 (19.6%)
2012 43 (13.2%)
2013 7 (2.2%)
Study type
PK/PD 53 (16.3%)
Primarily efficacy 182 (55.8%)
Efficacy and safety 21 (6.4%)
Primarily safety 70 (21.5%)
Planned trial completion before or after marketing authorisation
After 247 (75.8%)
Before 79 (24.2%)
Any extension of completion date
Yes 162 (49.7%)
No 164 (50.3%)
Any modification (excluding extensions)
Yes 201 (61.7%)
No 125 (38.3%)
Orphan drug status
Yes 48 (14.7%)
No 278 (85.3%)
The study cohort of paediatric trials relates to 122 new medicines that were centrally authorised by the EMA between
2010 and 2014 with paediatric requirements, of which 86 were initially authorised for use in adults only (see Methods
for details on cohort construction and definitions).
EMA, European Medicines Agency; PIP, paediatric investigation plan; PK/PD, pharmacokinetic/pharmacodynamics.
https://doi.org/10.1371/journal.pmed.1002520.t001
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study type. For completed trials, the median time to completion from the publication of the
PIP opinion was 3 years (IQR 1.5 to 4.4 years), and the median difference in planned and
reported completion dates was 0.2 years (IQR −0.3 to 1.3 years).
The unadjusted rate of trial completion for paediatric studies planned to be completed after
initial marketing authorisation was 23% (56 of 247), versus 86% (68 of 79) for trials planned to
be completed before authorisation (risk ratio 0.26; 95% CI 0.21–0.34; P< 0.001). In multivari-
able Cox regression models, trials planned to be completed after authorisation were associated
with an 89% lower likelihood of completion (hazard ratio [HR] 0.11; 95% CI 0.06–0.19; P<
0.001) than trials planned to be completed before marketing authorisation (Fig 2). Similar
results were obtained in a sensitivity analysis excluding PK/PD studies (S2 Table).
Similar results were also obtained in a sensitivity analysis limiting our analysis to paediatric
trials required for the 86 medicines initially authorised only in adults (S3 Table). As of 30
November 2017, 19% (39/203) of clinical trials for medicines authorised only in adults were
completed, compared to 38% for the full dataset. Trials planned to be completed after authori-
sation were associated with a similarly lower likelihood of completion (11% for studies planned
Table 2. Unadjusted rates of study completion and results reporting.
Characteristic Study completion, N (%) P value Results reporting, N (%) P value
Therapeutic area
Alimentary and metabolism 16 (36.4%) <0.001 13 (81.3%) 0.06
Blood 21 (48.8%) 16 (76.2%)
Cardiovascular 3 (21.4%) 3 (100.0%)
Genitourinary 2 (22.2%) 1 (50.0%)
Anti-infective 35 (46.7%) 29 (82.9%)
Antineoplastic and immunomodulatory 6 (13.6%) 3 (50.0%)
Neurologic 17 (32.1%) 16 (94.1%)
Respiratory 22 (78.6%) 22 (100.0%)
Musculoskeletal and others 2 (12.5%) 2 (100.0%)
Planned trial completion before or after marketing authorization
After 56 (22.7%) <0.001 47 (83.9%) 0.51
Before 68 (86.1%) 58 (85.3%)
Orphan drug status
Yes 18 (37.5%) 0.56 18 (100.0%) 0.04
No 106 (38.1%) 87 (82.1%)
Study type
PK/PD 27 (50.9%) 0.08 18 (66.7%) 0.04
Primarily efficacy 59 (32.4%) 52 (88.1%)
Efficacy and safety 8 (38.1%) 7 (87.5%)
Primarily safety 30 (42.9%) 28 (93.3%)
Any extension granted
Yes 59 (36.4%) 0.28 49 (83.1%) 0.41
No 65 (39.6%) 56 (86.2%)
Any modification granted
Yes 90 (44.8%) 0.01 73 (81.1%) 0.06
No 34 (27.2%) 32 (94.1%)
The composite endpoint of results reporting refers to (i) results posted on the EU Clinical Trials Register or ClinicalTrials.gov and/or (ii) publication in a peer-reviewed
journal. Results reporting is determined for completed trials only.
PK/PD, pharmacokinetic/pharmacodynamics.
https://doi.org/10.1371/journal.pmed.1002520.t002
Completion of clinical trials under the Paediatric Regulation in the European Union
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002520 March 1, 2018 9 / 15
to be completed after authorisation versus 79% for studies planned to be completed before
authorisation; HR 0.07; 95% CI 0.02–0.23; P< 0.001).
Fig 2. Cumulative incidence curves of paediatric trial completion. (a) Cumulative incidence rates of trial completion
for all paediatric trials. (b) Cumulative incidence rates of trial completion for efficacy and safety trials (i.e., excluding
PK/PD studies). Before/after initial MA refers to the planned completion date relative to the actual initial MA date.
MA, marketing authorisation; PIP, paediatric investigation plan; PK/PD, pharmacokinetic/pharmacodynamics.
https://doi.org/10.1371/journal.pmed.1002520.g002
Completion of clinical trials under the Paediatric Regulation in the European Union
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002520 March 1, 2018 10 / 15
Results reporting and publication of paediatric clinical trials
Among the 124 completed paediatric trials, the results were reported for 105 (85%) (Table 2).
The results for 63 (51%) trials were published both in a trial registry and a journal, the results
for 31 (25%) trials were posted only in a trial registry, and the results for 11 (9%) trials were
published in a journal but not available in a trial registry.
The median time to the composite endpoint of first results reporting (either in a trial regis-
try or peer-reviewed journal) was 4.7 years (IQR 3.2 to 5.8 years) from the date of publication
of the PIP, 1.8 years (IQR −0.1 to 2.8 years) from the date of initial marketing authorisation,
and 1.1 years (IQR 0.7 to 1.6 years) from the trial completion date. Substantively similar results
were obtained with logistic regression models.
Discussion
In this study of mandatory paediatric study requirements under the EU’s Paediatric Regula-
tion, we found that most paediatric studies have not yet been completed for new medicines
that were authorised for adult use between 2010 and 2014. After a median follow-up of 7 years
from publication of the PIP, 17% of medicines initially authorised for adults had completed all
required paediatric clinical trials, and 38% of paediatric studies had been completed. In addi-
tion, paediatric studies that were planned to be completed after initial marketing authorisation
were 89% less likely to be completed than studies planned to be completed before authorisa-
tion. This difference in likelihood of completion remained significant when considering only
efficacy and safety trials. Once trials were completed, the results for 85% of completed studies
were publicly reported in a trial registry or a peer-reviewed journal at a median of 1.1 years
after completion.
To our knowledge, this is the first study of the completion and results reporting of trials
required under the Paediatric Regulation, providing evidence on the performance of this regu-
lation in achieving important public health goals. This is timely as 2017 marks the 10-year
anniversary of the Paediatric Regulation’s entry into force in the EU [17,18]. The experience
over the past decade indicates that the Paediatric Regulation has contributed to increasing
numbers of paediatric trials and medicines available to children [18]. Yet, the full potential of
the Paediatric Regulation may not be realised if required paediatric studies are not completed
and reported rapidly and adequately. It is possible that delays in the conduct of paediatric trials
are justifiable in some cases, for instance if negative safety signals are observed in adult trials.
However, extensive delays in study completion hinder the ability of regulators and stakehold-
ers to achieve one of the primary aims of the Paediatric Regulation: to reduce the rate of off-
label use. The European Commission notes that deferred studies may become further delayed
because of recruitment difficulties once the product is available on the market, since parents
may be less willing to have their child participate in a trial if the medicine can already be pre-
scribed (even if off-label) [19].
Our study indicates that paediatric studies that are planned to be completed after marketing
authorisation are indeed less likely to be completed in a timely manner. These findings may
also help inform the oversight of paediatric studies in the US. In contrast to the EU’s Paediatric
Regulation, which is both mandatory and provides for a reward, in the US, the FDA operates 2
separate programmes to encourage paediatric drug development: one (the Best Pharmaceuti-
cals for Children Act) provides incentives but is voluntary [20,21], while the other (the Pediat-
ric Research Equity Act) establishes requirements for conducting certain paediatric studies but
does not provide incentives for doing so. Although the underlying legal bases differ between
the US and the EU, our study findings are broadly consistent with the experience with paediat-
ric studies in the US. Most paediatric studies that are required by the FDA are similarly
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deferred [22,23], and, as observed in this study, extension requests are frequently granted. As
of December 2016, the FDA reports that 71% (262/369) of deferred studies were granted fur-
ther extensions of their completion dates [24]. Finally, a recent study of drugs approved by the
FDA from 2003 to 2012 reported that 35% of drugs approved by the FDA without paediatric
assessments eventually submitted paediatric data, with a mean follow-up of 8.6 years from
approval [25].
Our findings underscore the lack of effective tools to enforce completion of important pae-
diatric studies once medicines become available on the market. Under the Paediatric Regula-
tion, the European Commission may impose financial penalties for infringement of the
obligations of the regulation, although no penalties have been assessed to date [4]. One
approach to improve the completion of paediatric studies could be to require more studies to
be completed before validating the initial marketing authorisation submission [18]. Another
potential approach could be to increase the reward, or to be able to tailor it using a pre-speci-
fied sliding scale, depending on the time it takes for required studies to be completed. Finally,
the conditions for allowing extensions to the planned completion date could be reviewed to
ensure that such requests account for the potential harms caused by delays in access to
information.
There were a number of limitations to our analysis. First, although our study provided a
median of 7 years of follow-up from the first publication date of the paediatric study require-
ments for the included medicines, it is possible that more of the required trials for these medi-
cines may be completed or published in the future. It is uncertain if and when such trials will
actually be completed. In one large study of paediatric clinical drug trials, the median trial
duration was 1.8 years [26]. Second, despite legal requirements for the registration and public
reporting of trial status, we cannot exclude the possibility that an additional number of appar-
ently incomplete trials may have already been completed. However, we crosschecked our
results across public and EMA internal regulatory sources, and we do not believe this possibil-
ity would substantially affect our study conclusions. We note that for all trials that were subject
to compliance checks by the EMA, the trial status reported to the EMA was consistent with
that reported on public registries. Finally, our study included paediatric studies required for
new medicines centrally authorised by the EMA, and our findings may not apply to unap-
proved products or to the relatively limited number of medicines that are authorised at the
national level.
Conclusions
The Paediatric Regulation was introduced in response to the serious harms caused by exposing
children to unauthorised and inadequately tested medicines. Our findings suggest that many
required paediatric studies have not been completed, with studies that are postponed to after
authorisation significantly less likely to be completed than those performed before authorisa-
tion. Policies to limit delays in study completion could accelerate the availability of clinically
valuable information on new medicines for children.
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